Kim Chan

Hak-Kim Chan is Professor in Pharmaceutics in the School of Pharmacy, Faculty of Medicine and Health at the University of Sydney, where he serves as Head of the Advanced Drug Delivery Group. He earned a BPharm with Medal from NDMC Taipei, followed by a PhD and DSc from the University of Sydney. Professor Chan is a world leader in respiratory drug delivery, with research spanning inhalation aerosols, powder production using novel processes, particle engineering, aerosol formulations, scintigraphic imaging of lung deposition, and clinical outcomes. His work addresses challenges in pulmonary drug delivery for conditions such as asthma, lung infections, and multidrug-resistant pathogens. He leads projects on inhalable bacteriophage powders, endolysin formulations, and dry powder inhalers, including combinations with probiotics and antibiotics for Pseudomonas aeruginosa eradication.

Since joining the University of Sydney over a decade ago, Professor Chan has authored more than 280 scientific publications, accumulating over 30,000 citations on Google Scholar with an h-index of 73. Notable publications include 'Spray Dried Powders and Powder Blends of Recombinant Human Deoxyribonuclease Using an Organic Solvent Free Process' (2001), 'Use of Solid Corrugated Particles to Enhance Powder Aerosol Performance' (2002), 'Formulation of Bacteriophage for Inhalation to Treat Multidrug-Resistant Pulmonary Infections' (2025), and 'Eradication of Pseudomonas aeruginosa using fixed-dose combination of probiotics and bacteriophages: development of an inhalable powder' (2025). His career includes prior roles as Researcher at Genentech (1992-1995) and Postdoctoral Fellow at the University of Minnesota Department of Pharmaceutics (1988-1989). Professor Chan has secured major funding, including ARC Linkage Grants, a US FDA grant over $500,000 in 2018 for inhaler development, and another FDA award in 2023 for affordable asthma inhalers. He holds the AAPS Fellowship and serves as Specialty Chief Editor for Respiratory Drug Delivery at Frontiers in Drug Delivery, as well as on the editorial board of the International Journal of Pharmaceutics. Additionally, he is a member of the University of Sydney Nano Institute and Sydney Infectious Diseases Institute.

Professional Email: kim.chan@sydney.edu.au